Jasper Therapeutics Inc
jaspertx.comJasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company developing mast cell-targeting therapies for allergic and inflammatory diseases. The company has no approved products and generates no product revenue, funding operations entirely through capital raises. Its lead candidate, briquilimab, is a subcutaneous anti-KIT antibody being studied in chronic urticaria and, until a July 2025 restructuring, in asthma. As of December 31, 2025, JSPR had an accumulated deficit of $316.7 million and federal net operating loss carryforwards of $210.4 million, with the company's auditors noting substantial doubt about its ability to continue as a going concern within one year of the March 30, 2026 filing date. Following a July 2025 corporate reorganization that cut the workforce by approximately 50%, the company narrowed its focus to briquilimab development in chronic urticaria and halted enrollment in its asthma and other clinical and preclinical programs.
Products & Services
Briquilimab: a subcutaneous anti-KIT monoclonal antibody targeting mast cell depletion. Active development focus as of December 31, 2025 is chronic urticaria. A Phase 1b asthma study (ETESIAN) reported preliminary results in December 2025 from 14 participants using a single 180mg dose, but enrollment was halted in July 2025 as part of the corporate reorganization. All other clinical and preclinical programs were also halted.
Revenue Model
Pre-revenue. No product sales or royalties as of the 10-K filed March 30, 2026. Operations are funded through external capital. Primary cash uses are research and development expenditures and general and administrative costs.
Customers & Markets
No commercial customers. End markets, if briquilimab is approved, would be patients with chronic urticaria and potentially asthma. Clinical development targets allergic and mast cell-driven inflammatory conditions.
Geographic Exposure
U.S.-domiciled company. No product revenue or commercial geographic presence disclosed in the filing. Regulatory commentary references both U.S. FDA pathways and European Union pricing and reimbursement frameworks.
Financial Snapshot
Loading...
